|
Middle Cerebral Artery Occlusion
|
0.310 |
Biomarker
|
disease |
CTD_human |
In this study, we found that Smox expression was increased in a rat middle cerebral artery occlusion (MCAO) model and in cultured primary neurons after oxygen-glucose deprivation and reoxygenation (OGD/R).
|
30576531 |
2019 |
|
Middle Cerebral Artery Occlusion
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
In this study, we found that Smox expression was increased in a rat middle cerebral artery occlusion (MCAO) model and in cultured primary neurons after oxygen-glucose deprivation and reoxygenation (OGD/R).
|
30576531 |
2019 |
|
Middle Cerebral Artery Syndrome
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Targeting Smox Is Neuroprotective and Ameliorates Brain Inflammation in Cerebral Ischemia/Reperfusion Rats.
|
30576531 |
2019 |
|
Middle Cerebral Artery Thrombosis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Targeting Smox Is Neuroprotective and Ameliorates Brain Inflammation in Cerebral Ischemia/Reperfusion Rats.
|
30576531 |
2019 |
|
Infarction, Middle Cerebral Artery
|
0.300 |
Biomarker
|
disease |
CTD_human |
Targeting Smox Is Neuroprotective and Ameliorates Brain Inflammation in Cerebral Ischemia/Reperfusion Rats.
|
30576531 |
2019 |
|
Middle Cerebral Artery Embolus
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Targeting Smox Is Neuroprotective and Ameliorates Brain Inflammation in Cerebral Ischemia/Reperfusion Rats.
|
30576531 |
2019 |
|
Left Middle Cerebral Artery Infarction
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Targeting Smox Is Neuroprotective and Ameliorates Brain Inflammation in Cerebral Ischemia/Reperfusion Rats.
|
30576531 |
2019 |
|
Embolic Infarction, Middle Cerebral Artery
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Targeting Smox Is Neuroprotective and Ameliorates Brain Inflammation in Cerebral Ischemia/Reperfusion Rats.
|
30576531 |
2019 |
|
Thrombotic Infarction, Middle Cerebral Artery
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Targeting Smox Is Neuroprotective and Ameliorates Brain Inflammation in Cerebral Ischemia/Reperfusion Rats.
|
30576531 |
2019 |
|
Right Middle Cerebral Artery Infarction
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Targeting Smox Is Neuroprotective and Ameliorates Brain Inflammation in Cerebral Ischemia/Reperfusion Rats.
|
30576531 |
2019 |
|
Mood Disorders
|
0.300 |
Biomarker
|
group |
PSYGENET |
Overall, each gene was associated with at least one main outcome: anxiety (SAT1, SMS), mood disorders (SAT1, SMOX), and suicide attempts (SAT1, OATL1).
|
21152090 |
2010 |
|
Cerebrovascular accident
|
0.300 |
Biomarker
|
group |
CTD_human |
After the onset of stroke, an increase in AcPAO first occurred, followed by increased levels of SMO and finally acrolein.
|
16269634 |
2005 |
|
Acute Cerebrovascular Accidents
|
0.300 |
Biomarker
|
disease |
CTD_human |
Polyamine oxidase and acrolein as novel biochemical markers for diagnosis of cerebral stroke.
|
16269634 |
2005 |
|
Malignant neoplasm of breast
|
0.300 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Cystic Fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
<i>Pseudomonas aeruginosa</i> is an opportunistic pathogen found ubiquitously in the environment and commonly associated with airway infection in patients with cystic fibrosis.<i>P. aeruginosa</i> strain PAO1 is one of the most commonly used laboratory-adapted research strains and is a standard laboratory-adapted strain in multiple laboratories and strain banks worldwide.
|
30530517 |
2019 |
|
Cystic Fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Twenty-four hour biofilms formed by the P. aeruginosa strain PAO1 and cystic fibrosis (CF) isolates were tested for susceptibility to oxyclozanide and tobramycin killing using BacTiter-Glo™ and cfu.
|
30624737 |
2019 |
|
White Blood Cell Count procedure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Red cell distribution width determination
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Finding of Mean Corpuscular Hemoglobin
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
RDW - Red blood cell distribution width result
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Cystic Fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
While a reduction in cell growth was observed after 8 h of CORM application, either no effect or even a slight increase in cell densities and the amount of biofilm was observed after 24 h. This variation could be partly explained by differences in bacterial virulence traits: while CF isolates showed attenuated <i>in vivo</i> virulence and growth compared to strain PAO1, they formed much more biofilm, which could have potentially protected them from the CORM.
|
29472912 |
2018 |
|
Cystic Fibrosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
By exploiting this unstable phenotype, we isolated 34 spontaneous nonmucoid variants arising from the mucoid strain PDO300, a PAO1 derivative containing the <i>mucA22</i> allele commonly found in mucoid CF isolates.
|
29784885 |
2018 |
|
Cystic Fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present study, we evaluate the volatile metabolites produced by P. aeruginosa (PAO1)-infected, RSV-infected, co-infected, or uninfected CF bronchial epithelial (CFBE) cells, in vitro.
|
29735804 |
2018 |
|
Cystic Fibrosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the present work, P. aeruginosa strain PAO1, and four multidrug resistant (MDR) isolates from chronically infected CF individuals, were grown as 48-hour biofilms in a static biofilm slide chamber model.
|
30283025 |
2018 |